# Efficacy of Gemcitabine Submucosal Injection for Preventing Recurrence in Intermediate- and High-Risk Non-Muscle-Invasive Bladder Cancer: A Randomized Trial

> **NCT07198451** · PHASE2,PHASE3 · NOT_YET_RECRUITING · sponsor: **Shanghai University of Traditional Chinese Medicine** · enrollment: 320 (estimated)

## Conditions studied

- Non Muscle Invasive Bladder Cancer

## Interventions

- **DRUG:** Gemcitabine Submucosal Injection
- **DRUG:** Gemcitabine Intravesical Instillation

## Key facts

- **NCT ID:** NCT07198451
- **Lead sponsor:** Shanghai University of Traditional Chinese Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-10
- **Primary completion:** 2028-05
- **Final completion:** 2028-06
- **Target enrollment:** 320 (ESTIMATED)
- **Last updated:** 2025-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07198451

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07198451, "Efficacy of Gemcitabine Submucosal Injection for Preventing Recurrence in Intermediate- and High-Risk Non-Muscle-Invasive Bladder Cancer: A Randomized Trial". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07198451. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*